skip to main content

Artica Therapeutics

Transforming drug discovery

Artica Therapeutics is focusing on the development of small molecule medicines to treat diseases of high unmet medical need, e.g. inflammatory diseases. The company has developed specific expertise to target so-called G protein-coupled receptors (GPCRs), which were previously difficult to target for drug development.

To equip the R&D facilities at the Leiden Bio Science Park, the company has successfully applied for a Mibiton lease funding.

Tjeerd Bart, CEO

"The support of Mibiton has enabled Artica to accelerate its drug discovery and development programs, unlock the full potential of its unique technology platform and generate innovative and life-changing medicines."